Tomas Hanke

Prof. Tomas Hanke

Oxford University
+1
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2017 in Nature Immunology
Verified
Journal Article
Closed access
LJLouise Johnson
Louise Johnson
SBSuneale Banerji
Suneale Banerji
WLWilliam Lawrance
William Lawrance
UGUzi Gileadi
Uzi Gileadi
GPGennaro Prota
Gennaro Prota
David G. JacksonDavid G. Jackson
David G. Jackson

1 February 2014 in Molecular Therapy
Verified
Journal Article
Open access
NBNicola Borthwick
Nicola Borthwick
TATina Ahmed
Tina Ahmed
BOBeatrice Ondondo
Beatrice Ondondo
PHPeter Hayes
Peter Hayes
ARAnnie Rose
Annie Rose
THTomas Hanke
Tomas Hanke
Virus diversity and escape from immune responses are the biggest challenges to the development of an effective vaccine against HIV-1. We hypothesized that T-cell vaccines targeting the most conserved regions of the HIV-1 proteome, which are common to most variants and bear fitness costs when mutated, will generate effectors that efficiently recognize and kill virus-infected cells early enough after transmission to potentially impact on HIV-1 replication and will do so more efficiently than whole protein-based T-cell vaccines. Here, we describe the first-ever administration of conserved immunogen vaccines vectored using prime-boost regimens of DNA, simian adenovirus and modified vaccinia virus Ankara to uninfected UK volunteers. The vaccine induced high levels of effector T cells that recognized virus-infected autologous CD4(+) cells and inhibited HIV-1 replication by up to 5.79 log10. The virus inhibition was mediated by both Gag- and Pol- specific effector CD8(+) T cells targeting epitopes that are typically subdominant in natural infection. These results provide proof of concept for using a vaccine to target T cells at conserved epitopes, showing that these T cells can control HIV-1 replication in vitro.

1 April 2016 in Molecular Therapy
Verified
Journal Article
Open access
BOBeatrice Ondondo
Beatrice Ondondo
HMHayato Murakoshi
Hayato Murakoshi
GCGenevieve Clutton
Genevieve Clutton
SASultan Abdul-Jawad
Sultan Abdul-Jawad
EWEdmund G-T Wee
Edmund G-T Wee
THTomas Hanke
Tomas Hanke
An effective HIV-1 vaccine is the best solution for halting the AIDS epidemic. Here, we describe the design and preclinical immunogenicity of T-cell vaccine expressing novel immunogens tHIVconsvX, vectored by DNA, simian (chimpanzee) adenovirus and poxvirus MVA, a combination highly immunogenic in humans. The tHIVconsvX immunogens combine the three leading strategies for elicitation of effective CD8+ T cells: use of regions of HIV-1 proteins functionally conserved across all M group viruses (to make HIV-1 escape costly on viral fitness), inclusion of bivalent complementary mosaic immunogens (to maximize global epitope matching and breadth of responses, and block common escape paths), and inclusion of epitopes known to be associated with low viral load in infected untreated people (to induce field-proven protective responses). tHIVconsvX was highly immunogenic in two strains of mice. Furthermore, the magnitude and breadth of CD8+ T-cell responses to tHIVconsvX-derived peptides in treatment-naive HIV-1+ patients significantly correlated with high CD4+ T-cell count and low viral load. Overall, the tHIVconsvX design, combining the mosaic and conserved-region approaches, provides an indisputably better coverage of global HIV-1 variants than previous T-cell vaccines. These immunogens delivered in a highly immunogenic framework of adenovirus prime and MVA boost are ready for clinical development.

15 February 2015 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
BMBeatriz Mothe
Beatriz Mothe
XHXintao Hu
Xintao Hu
ALAnuska Llano
Anuska Llano
MRMargherita Rosati
Margherita Rosati
AOAlex Olvera
Alex Olvera
CBChristian Brander
Christian Brander
None of the HIV T-cell vaccine candidates that have reached advanced clinical testing have been able to induce protective T cell immunity. A major reason for these failures may have been suboptimal T cell immunogen designs. To overcome this problem, we used a novel immunogen design approach that is based on functional T cell response data from more than 1,000 HIV-1 clade B and C infected individuals and which aims to direct the T cell response to the most vulnerable sites of HIV-1. Our approach identified 16 regions in Gag, Pol, Vif and Nef that were relatively conserved and predominantly targeted by individuals with reduced viral loads. These regions formed the basis of the HIVACAT T-cell Immunogen (HTI) sequence which is 529 amino acids in length, includes more than 50 optimally defined CD4+ and CD8+ T-cell epitopes restricted by a wide range of HLA class I and II molecules and covers viral sites where mutations led to a dramatic reduction in viral replicative fitness. In both, C57BL/6 mice and Indian rhesus macaques immunized with an HTI-expressing DNA plasmid (DNA.HTI) induced broad and balanced T-cell responses to several segments within Gag, Pol, and Vif. DNA.HTI induced robust CD4+ and CD8+ T cell responses that were increased by a booster vaccination using modified virus Ankara (MVA.HTI), expanding the DNA.HTI induced response to up to 3.2% IFN-γ T-cells in macaques. HTI-specific T cells showed a central and effector memory phenotype with a significant fraction of the IFN-γ+ CD8+ T cells being Granzyme B+ and able to degranulate (CD107a+). These data demonstrate the immunogenicity of a novel HIV-1 T cell vaccine concept that induced broadly balanced responses to vulnerable sites of HIV-1 while avoiding the induction of responses to potential decoy targets that may divert effective T-cell responses towards variable and less protective viral determinants.

1 March 2019 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
NMNathifa Moyo
Nathifa Moyo
AVAnnette B. Vogel
Annette B. Vogel
SBSøren Buus
Søren Buus
SEStephanie Erbar
Stephanie Erbar
EWEdmund G. Wee
Edmund G. Wee
THTomas Hanke
Tomas Hanke
Focusing T cell responses on the most vulnerable parts of HIV-1, the functionally conserved regions of HIV-1 proteins, is likely a key prerequisite for vaccine success. For a T cell vaccine to efficiently control HIV-1 replication, the vaccine-elicited individual CD8+ T cells and as a population have to display a number of critical traits. If any one of these traits is suboptimal, the vaccine is likely to fail. Fine-tuning of individual protective characteristics of T cells will require iterative stepwise improvements in clinical trials. Although the second-generation tHIVconsvX immunogens direct CD8+ T cells to predominantly protective and conserved epitopes, in the present work, we have used formulated self-amplifying mRNA (saRNA) to deliver tHIVconsvX to the immune system. We demonstrated in BALB/c and outbred mice that regimens employing saRNA vaccines induced broadly specific, plurifunctional CD8+ and CD4+ T cells, which displayed structured memory subpopulations and were maintained at relatively high frequencies over at least 22 weeks post-administration. This is one of the first thorough analyses of mRNA vaccine-elicited T cell responses. The combination of tHIVconsvX immunogens and the highly versatile and easily manufacturable saRNA platform may provide a long-awaited opportunity to define and optimize induction of truly protective CD8+ T cell parameters in human volunteers.

31 October 2013 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
LCLiye Chen
Liye Chen
Roman FischerRoman Fischer
Roman Fischer
YPYanchun Peng
Yanchun Peng
EREmma Reeves
Emma Reeves
KMKirsty McHugh
Kirsty McHugh
PBPaul Bowness
Paul Bowness
Objective: HLA–B27 and endoplasmic reticulum aminopeptidase 1 (ERAP1) are the two strongest genetic factors predisposing to ankylosing spondylitis (AS). A key aminopeptidase in class I major histocompatibility complex presentation, ERAP1 potentially contributes to the pathogenesis of AS by altering HLA–B27 peptide presentation. The aim of this study was to analyze the effects of ERAP1 on the HLA–B27 peptide repertoire and peptide presentation to cytotoxic T lymphocytes (CTLs).Methods: ERAP1‐silenced and ‐competent HeLa.B27 and C1R.B27 cells were isotope‐labeled, mixed, lysed, and then immunoprecipitated using W6/32 or ME1 antibodies. Peptides bound to HLA–B27 were eluted and analyzed by tandem mass spectrometry. Selected peptides were synthesized and tested for HLA–B27 binding ability. The effect of ERAP1 silencing/mutation on presentation of an immunodominant viral HLA–B27 epitope, KK10, to CTLs was also studied.Results: In both HeLa.B27 and C1R.B27 cells, the proportion of 9‐mer HLA–B27–bound peptides was decreased by ERAP1 silencing, whereas the percentages of longer peptides (11–13 mer) were increased. Surprisingly, following ERAP1 silencing, C‐terminally extended peptides were readily identified. These were better able to bind to HLA–B27 than were N‐terminally extended peptides lacking an arginine at position 2. In both HeLa.B27 cells and mouse fibroblasts expressing HLA–B27, the absence of ERAP1 reduced peptide recognition by HLA–B27–restricted KK10‐specific CTLs following infection with recombinant vaccinia virus or transfection with minigenes expressing KK10 precursors. Presence of an AS‐protective variant of ERAP1, K528R, as compared to wild‐type ERAP1, reduced the peptide recognition by KK10 CTLs following transfection with extended KK10 minigenes.Conclusion: These results show that ERAP1 directly alters peptide binding and presentation by HLA–B27, thus demonstrating a potential pathogenic mechanism in AS. Inhibition of ERAP1 could potentially be used for treatment of AS and other ERAP1‐associated diseases.